H.C. Wainwright analyst Raghuram Selvaraju increased the price target on Replimune Group (NASDAQ:REPL), currently trading at $13.79 with a market cap of $1.06 billion, to $22.00, up from the previous ...
19m
U.S. applications for unemployment benefits fell last week as employers continue to retain workers despite resurgent ...
Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699, expectations were $-1.32. Operator: Good day and thank you for standing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback